Liver's "Sleep Timer" Mechanism Discovered in Chronic Hepatitis B

Scientists at the Technical University of Munich have uncovered a novel mechanism in chronic hepatitis B that explains why certain immune cells fail to combat the virus effectively. Published in Nature, the research reveals that endothelial cells lining liver blood vessels initiate a "sleep timer" in cytotoxic T cells, gradually diminishing their ability to recognize and destroy hepatitis B-infected liver cells.

The study shows that when T cells come into contact with infected hepatocytes through openings in the endothelial cells, a molecular countdown begins. Dr. Miriam Bosch, the study's lead author, explains, "The longer the T cells are in contact with the endothelial cells, the weaker their activity becomes." This process involves the cAMP-PKA pathway, which effectively shuts down the T cells' signal transmission, preventing them from attacking infected cells and proliferating.

Professor Percy Knolle, who led the research team, suggests this mechanism likely evolved as a protective measure for the liver, preventing excessive immune cell proliferation that could cause critical organ damage. However, in chronic hepatitis B, this protective feature may inadvertently allow the virus to evade immune control, leading to ongoing liver damage despite the presence of potentially effective immune cells.

This discovery opens up new avenues for developing targeted immunotherapies for chronic hepatitis B. Potential approaches include manipulating T cells to resist the endothelial cells' signals or using small molecules to disrupt the sleep timer mechanism. However, researchers emphasize the importance of delivering such treatments selectively to liver immune cells to avoid interfering with vital processes elsewhere in the body.